Cipla said that its wholly owned subsidiary Invagen Pharmaceuticals has entered into a strategic partnership with Qilu Pharmaceutical Co. for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda (pembrolizumab), for United States.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.